Funds holding Olema Pharmaceuticals Inc
ISIN US68062P1066 · United States
- Fund holders
- 217
- Of which ETFs
- 44 173 other funds
- Value held
- ≈ 388M $ 381.4M $ · 63M SEK
- Share of capital
- 36.0 % of 87.5M shares on Aug 6, 2026
217 funds hold this company. This table lists the 216 that declare it in a regulatory filing. 1 more fund publishes its holdings in its own report. The “Fund reports” tab lists it, with its weight.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Russell 2000 2x Strategy Fund Rydex Dynamic Funds | 422 | 5.3K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Small Company Value Portfolio Wilshire Mutual Funds Inc | 420 | 5.3K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator ETFs Trust | 394 | 4.5K $ | 0.04 % | 0.00 % | as of Jul 31, 2026 ↗ |
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 354 | 4.4K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 344 | 4.3K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 322 | 4K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Putnam VT Global Asset Allocation Fund Putnam Variable Trust | 305 | 3.8K $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Fidelity Enhanced Small Cap Growth ETF Fidelity Covington Trust | 286 | 3.6K $ | 0.06 % | 0.00 % | as of Jun 30, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 210 | 2.6K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 194 | 2.4K $ | 0.01 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 116 | 1.5K $ | 0.02 % | 0.00 % | as of Jun 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 79 | 988.3 $ | 0.03 % | 0.00 % | as of Jun 30, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 66 | 755.7 $ | 0.01 % | 0.00 % | as of Jul 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 65 | 857.4 $ | 0.00 % | 0.00 % | as of May 31, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 22 | 275.2 $ | 0.00 % | 0.00 % | as of Jun 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 20 | 263.8 $ | 0.02 % | 0.00 % | as of May 31, 2026 ↗ |
Funds that publish their own holdings
| Fund | Weight in fund | |
|---|---|---|
| Pictet - Biotech Pictet Asset Management (Europe) S.A. | 0.61 % | as of Sep 30, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Virtus Biotech Clinical Trials Etf ETFis Series Trust I | 0.78 % | as of Jul 31, 2026 ↗ |
| Dunham Small Cap Growth Fund Dunham Funds | 0.71 % | as of Jul 31, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 0.66 % | as of May 31, 2026 ↗ |
| PGIM Jennison Health Sciences Fund Prudential Sector Funds, Inc. | 0.63 % | as of May 29, 2026 ↗ |
| Pictet - Biotech Pictet Asset Management (Europe) S.A. | 0.61 % | as of Sep 30, 2025 ↗ |
| Tema Oncology ETF Tema ETF Trust | 0.60 % | as of May 31, 2026 ↗ |
| Franklin Biotechnology Discovery Fund Franklin Strategic Series | 0.56 % | as of Jul 31, 2026 ↗ |
| Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value Fund Federated Hermes Equity Funds | 0.49 % | as of Jun 30, 2026 ↗ |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 0.40 % | as of Jul 31, 2026 ↗ |
| Fidelity Disruptive Medicine ETF Fidelity Covington Trust | 0.36 % | as of May 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 213 | -3 | 31,055,419 | +17.3 % |
| 2026Q2 | 216 | +34 | 26,477,013 | +35.9 % |
| 2026Q1 | 182 | +50 | 19,484,759 | +84.6 % |
| 2025Q4 | 132 | -2 | 10,553,327 | -3.9 % |
| 2025Q3 | 134 | -20 | 10,982,120 | +19.6 % |
| 2025Q2 | 154 | +1 | 9,181,494 | -9.3 % |
| 2025Q1 | 153 | 0 | 10,128,364 | +0.3 % |
| 2024Q4 | 153 | +8 | 10,098,023 | +5.8 % |
| 2024Q3 | 145 | -4 | 9,544,778 | -14.1 % |
| 2024Q2 | 149 | +9 | 11,110,422 | +25.2 % |
| 2024Q1 | 140 | +18 | 8,876,528 | +35.3 % |
| 2023Q4 | 122 | 6,560,182 |
Institutional managers
188 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| FMR LLC | 10,386,845 | 154.9M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 8,020,576 | 119.6M $ | as of Mar 31, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7,473,238 | 111.4M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 7,108,488 | 106M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 5,652,135 | 84.3M $ | as of Mar 31, 2026 |
| BVF INC/IL | 5,295,893 | 79M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 4,756,949 | 70.9M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 3,937,831 | 58.7M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 3,900,000 | 58.1M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 3,208,875 | 47.8M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 2,600,000 | 38.8M $ | as of Mar 31, 2026 |
| JENNISON ASSOCIATES LLC | 1,822,123 | 27.2M $ | as of Mar 31, 2026 |
| Polar Capital Holdings Plc | 1,602,970 | 23.9M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,544,417 | 23M $ | as of Mar 31, 2026 |
| Defilade Capital Management, L.P. | 1,504,536 | 22.4M $ | as of Mar 31, 2026 |
| Woodline Partners LP | 1,482,030 | 22.1M $ | as of Mar 31, 2026 |
| LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 1,355,299 | 20.2M $ | as of Mar 31, 2026 |
| FRANKLIN RESOURCES INC | 1,218,957 | 18.2M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 1,215,690 | 18.1M $ | as of Mar 31, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1,182,836 | 17.6K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 1,169,421 | 17.4M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,082,434 | 16.1M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,045,589 | 15.6M $ | as of Mar 31, 2026 |
| Duquesne Family Office LLC | 986,827 | 14.7K $ | as of Mar 31, 2026 |
| CITADEL ADVISORS LLC | 905,332 | 13.5M $ | as of Mar 31, 2026 |
Declared shareholders of Olema Pharmaceuticals Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| FMR LLC and 1 other | 13.80 % | 12,075,062 | as of Jun 30, 2026 · SCHEDULE 13G |
| BlackRock, Inc. | 7.10 % | 6,244,212 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Olema Pharmaceuticals Inc". https://titelia.com/en/stocks/olema-pharmaceuticals-inc-US68062P1066